Neuroblastoma (NB) is a genetically heterogeneous tumor characterized by pleomorphic cells, including those with MYCN amplification that are highly glycolytic, presenting the opportunity to use glycolytic inhibitor 2-deoxyglucose (2DG) to suppress NB cell growth [1,2]. This evidence concerns the gene MYCN and neuroblastoma.